These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. Shah A; O'Neill J; Feldman SR J Drugs Dermatol; 2010 Dec; 9(12):1491-4. PubMed ID: 21120256 [TBL] [Abstract][Full Text] [Related]
26. Calcipotriene/betamethasone foam (Enstilar) for psoriasis. Med Lett Drugs Ther; 2016 Apr; 58(1492):48-9. PubMed ID: 27049509 [No Abstract] [Full Text] [Related]
27. [Methotrexate in psoriasis: do we need to give a test dose?]. Carretero-Hernández G Actas Dermosifiliogr; 2012; 103(1):1-4. PubMed ID: 22093543 [No Abstract] [Full Text] [Related]
28. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. Manalo IF; Gilbert KE; Wu JJ J Drugs Dermatol; 2015 Oct; 14(10):1086-8. PubMed ID: 26461817 [No Abstract] [Full Text] [Related]
30. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis. Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729 [TBL] [Abstract][Full Text] [Related]
31. Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment. Braun GS; Witt M; Mayer V; Schmid H Int J Dermatol; 2007 Dec; 46(12):1315-7. PubMed ID: 18173537 [No Abstract] [Full Text] [Related]
32. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Ryan C; Kirby B; Collins P; Rogers S Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535 [TBL] [Abstract][Full Text] [Related]
33. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969 [TBL] [Abstract][Full Text] [Related]
34. Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. Liu M; Huang YY; Hsu S; Kass JS CNS Drugs; 2016 Dec; 30(12):1149-1168. PubMed ID: 27832476 [TBL] [Abstract][Full Text] [Related]
35. High-concentration (20 μg g⁻¹ ) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial. Choi JW; Choi JW; Kwon IH; Youn JI Br J Dermatol; 2010 Jun; 162(6):1359-64. PubMed ID: 20302582 [TBL] [Abstract][Full Text] [Related]
36. Drug-induced acute pancreatitis associated with 22-oxacalcitriol ointment for treatment of psoriasis. Sato M; Takamura M; Sato Y; Yokoyama H; Nozawa Y; Masui Y; Miida H; Hashimoto T; Ito M; Aoyagi Y JOP; 2009 May; 10(3):336-7. PubMed ID: 19454832 [No Abstract] [Full Text] [Related]
37. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Kragballe K; Austad J; Barnes L; Bibby A; de la Brassinne M; Cambazard F; Fleming C; Heikkilä H; Jolliffe D; Peyri J; Svensson A; Toole J; Wozel G Br J Dermatol; 2006 Jun; 154(6):1155-60. PubMed ID: 16704648 [TBL] [Abstract][Full Text] [Related]
38. Initial experience with routine administration of etanercept in psoriasis. de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432 [TBL] [Abstract][Full Text] [Related]